Myriad Genetics, Inc.
(NASDAQ : MYGN)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. 8.53%147.380.0%$973.12m
AMGNAmgen, Inc. 0.61%254.601.5%$857.20m
GILDGilead Sciences, Inc. 0.35%64.701.0%$546.77m
VRTXVertex Pharmaceuticals, Inc. 1.42%273.471.9%$494.63m
REGNRegeneron Pharmaceuticals, Inc. 1.25%691.952.6%$439.95m
ILMNIllumina, Inc. 5.90%257.933.3%$331.94m
NVAXNovavax, Inc. 17.10%55.1275.7%$302.64m
BIIBBiogen, Inc. 0.86%205.981.8%$234.71m
BNTXBioNTech SE 5.29%166.520.0%$222.15m
SNSSSunesis Pharmaceuticals, Inc. 1.91%2.140.7%$149.59m
EXASEXACT Sciences Corp. 7.50%53.6017.7%$137.81m
TECHBio-Techne Corp. 5.71%386.164.5%$106.03m
TXG10X Genomics, Inc. 11.30%52.700.0%$105.86m
BMRNBioMarin Pharmaceutical, Inc. 2.50%80.834.2%$96.91m
CRSPCRISPR Therapeutics AG 5.09%58.040.6%$84.49m

Company Profile

Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic tests. It operates through the Diagnostics and Other segments. The Diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual's risk of developing a disease later in life. The Other segment offers testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and also includes corporate services. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.